[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of XXXX with advanced @entity1149 ].

@entity1 @entity137 @entity417 @entity1149 @entity1726 @entity56 @entity1431 @entity811
BACKGROUND AND OBJECTIVE: The platinum-containing combination chemotherapy has been proved to be benefit to the @entity1 with advanced @entity1149 . Compared with cisplatin-based combination chemotherapy regimens, carboplatin-based regimens result in longer survival time and less @entity137 , despite of lower response rate. In the palliative treatment setting, less @entity137 and longer survival may be more significant than response rate. So we choose the carboplatin-based combination chemotherapy regimens as our study objects. To compare the efficacy and @entity137 of two carboplatin-based combination chemotherapy regimens: paclitaxel and carboplatin regimen(PC) vs ifosfamide, etoposide, and carboplatin regimen(IEC). METHODS: Sixty-eight @entity1 were enrolled in this study, 35 @entity1 received PC regimen and 33 received IEC regimen. @entity1 in both groups were well-matched with baseline disease characteristics(P > 0.05). RESULTS: In PC group, the response rate was 40.0% (14/35, 95% confidence interval [CI]: 23.8%-56.2%) (14 PR, 19 NC, 2 @entity1726 ). Whereas in group IEC, the response rate was 21.2% (7/33, 95% CI: 7.3%-35.1%) (7 PR, 24 NC, 2 @entity1726 ). The median survival and 1-year survival rate were 9.1 months (95% CI: 7.2-11.0 months) and 25.7% (95% CI: 11.2%-40.2%) for group PC versus 7.8 months (95% CI: 6.2-9.4 months) and 20.0% (95% CI: 6.0%-34.0%) for group IEC. The better response rate, 1-year survival rate, and the longer median survival seen in the group PC were not statistically significant (for response rate, P = 0.094, Chi-square test; for overall survival, P = 0.684, Log-rank test). The hematologic @entity137 , especially @entity1431 (P < 0.0005, Wilcoxon rank sum test) and @entity417 (P = 0.006, Wilcoxon rank sum test) were less pronounced in group PC; @entity811 and fever were pronounced more in group IEC, whereas @entity56 was more in group PC, but there were no statistically significant differences between the two groups(P > 0.05, Wilcoxon rank sum test); Other @entity137 were similar. CONCLUSIONS: Compared with IEC regimen, PC regimen result in less hematologic @entity137 in the @entity1 with advanced NSCLC, Although whether its efficacy was better should be confirmed by well-controlled randomized clinical trials with more @entity1 .
